An interventional study of Neck dissection followed by radiotherapy(50Gy) according to risk factors and Definitive radiotherapy in Hypopharyngeal Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-12-12.
Sponsored by Tianjin Medical University Cancer Institute and Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hypopharyngeal Neoplasms with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Hypopharyngeal Neoplasms · China.
Among the 21 studies in Hypopharyngeal Neoplasms with a site in China, this one is the 3rd largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 4 with no phase, reaches primary completion later than 2 of the 16 other live ones, and was the 3rd registered.
148 studies on the registry are indexed under Hypopharyngeal Neoplasms; 45 are open to participants now.
Browse Hypopharyngeal Neoplasms studies →16 of the 21 studies in Hypopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–100 · Healthy volunteers
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–75
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–90
Sun Yat-sen University · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Hypopharyngeal Neoplasms studies recruiting now, 23 (61%) set no upper age limit and 8 (21%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 59 across 110 interventional studies indexed under Hypopharyngeal Neoplasms.
Median enrollment 63 across the 19 interventional studies, 2,000 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 494 studies on the registry; 293 are open to participants now.
Tianjin Medical University Cancer Institute and Hospital has 1 study filed under Hypopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypopharyngeal Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137039The First Affiliated Hospital of Xiamen UniversityNeoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | 2027-08-20 |
| NCT06039631Fudan UniversityNeoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | 2027-09-01 |
| NCT05494190Eye & ENT Hospital of Fudan UniversityThe Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma | 2027-11 |
| NCT07248956Eye & ENT Hospital of Fudan UniversityNeoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Hypopharyngeal Neoplasms with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
At the time of diagnosis, approximately 60%-80% of patients with hypopharyngeal cancer are found with cervical lymph node metastasis. Cervical nodal metastasis is an important prognostic factor in hypopharyngeal cancer. Induction chemotherapy is frequently used in advanced hypopharynx cancer. However, sometimes CR was obtained at the tumor's primary site but not in the palpable lymph nodes in the neck, the large cervical lymph node metastasis poorly responded to induction chemotherapy in a considerable percentage of patients. At present, patients with primary tumor achieved CR preferred to receive definitive radiotherapy no matter cervical lymph node metastasis SD or progression. But, radiotherapy was poor effective to the big cervical lymph node metastasis, because the inner of big cervical lymph node metastasis was hypoxic and necrosis. The investigators conducted a prospective, randomised trial to compare neck dissection with definitive radiotherapy for advanced hypopharyngeal cancer cervical lymph node metastasis with poor response to induction chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neck dissection followed by radiotherapy(50Gy) according to risk factors
Procedure: Neck dissection followed by radiotherapy(50Gy) according to risk factors
Definitive radiotherapy (70Gy)
Radiation: Definitive radiotherapy
Neck dissection followed by radiotherapy(50Gy) according to risk factors
Definitive radiotherapy (70Gy)
Neck control rates
The percentage of patients without cervical lymph node metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 1 year
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 3 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 5 years
Overall survival
The proportion of patients who survived
Time frame: 3 years
Overall survival
The proportion of patients who survived
Time frame: 5 years
Quality of life(QOL) QLQ-C30
Evaluated by the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30
Time frame: 1 year
Quality of life(QOL) QLQ-HN35
Evaluated by the European Organization for Research and Treatment of Cancer(EORTC) QLQ-HN35
Time frame: 1 year
Start is estimated for Jan 2018; primary completion for Jan 2024, 72 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Medical University Cancer Institute and Hospital →